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A B S T R A C TObjectives: We use a contingent valuation (CV) study of childhood
asthma to discuss a central issue in designing CV studies of chronic
illness—the need for a detailed, realistic scenario that minimizes
confounding factors—and show how to address this issue. We apply
our methodology to estimate households’ willingness to pay (WTP) for
reductions in asthma morbidity. Methods: By using a combination of
focus groups, revealed preference surveys, and epidemiological sur-
veys, we gathered information on health status, attitudes, and beliefs
regarding asthma, risk-averting behaviors, perceptions of these beha-
viors, and household socioeconomic characteristics. We used this
information to design a CV survey that we extensively tested for
validity. In the survey, we elicited participants’ WTP for a hypothetical
device that would reduce symptom-days by improving asthma man-
agement; these data enabled us to estimate household WTP by using a
variety of econometric models. Results: Our analysis of households
with children with asthma yielded the following conclusions: the
scenario should address both physical asthma symptoms and thent matter Copyright & 2012, International Society
r Inc.
.1016/j.jval.2012.07.006
dt@gmail.com.
ondence to: Sylvia Brandt, Department of Resource
.psychosocial stress of managing a chronic illness; the survey should
measure household perceptions of the burden of asthma in addition
to objective measures such as symptom-days; and the scenario
should not involve substantial behavioral changes or a new medica-
tion, to avoid confounding household preferences with unrelated
attributes of the scenario. Our primary models estimated mean
household WTP for a 50% reduction in symptom-days (and accom-
panying reductions in psychosocial stress) at $56.48 to $64.84
per month. Conclusions: Our methodology can be used to inform
CV studies of chronic illness. Our WTP estimates can help regulatory
agencies assess a wide range of policies that affect the incidence or
severity of asthma.
Keywords: asthma, attitudes and beliefs, chronic illnesses, contingent
valuation, quality of life.
Copyright & 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Globally, more than 300 million people suffer from asthma,
leading to approximately 15 million disability-adjusted life-years
annually; an estimated 1 in every 250 deaths internationally is
due to asthma [1]. In the United States, the cost of asthma was
more than $37 billion in 2007 [2]. More generally, chronic illnesses
are internationally the leading cause of mortality and disease
burden [3], costing approximately $1.5 trillion annually in the
United States [4].
Developing accurate tools for valuing changes in chronic
illness is a high priority for health economics. In this article, we
discuss a central design issue in valuing chronic illness and
address this issue in the context of childhood asthma. To capture
the total welfare impact of asthma on households, we chose the
contingent valuation (CV) method over alternatives such as the
cost-of-illness approach or the revealed preference method. We
estimated a parent’s willingness to pay (WTP) to reduce her child’s
asthma morbidity by surveying participants in an epidemiological
study of children’s asthma, combining data on households with arevealed preference survey and the CV survey. To ensure that the
WTP values we estimated were most informative for policy and
program evaluation, we administered the CV survey to parents
whose children currently have asthma symptoms and we speci-
fied that respondents would pay out of pocket for the hypothetical
good. Thus, our data correspond to the privately financed, private
goods scenario (described by Shackley and Donaldson [5]) and are
appropriate for our suggested uses.
Because household quality of life is affected by both physical
asthma symptoms and uncertainty about when an attack might
occur, a valuation scenario should reduce both the frequency
of asthma episodes and the accompanying psychosocial stress.
The survey should measure the household’s perception of its
asthma burden in addition to objective data such as the number
of symptom-days. Finally, the scenario should not require sub-
stantial behavioral changes or new medications, so that stated
values do not reflect unrelated household preferences.
To promote the development of guidelines for health valua-
tion, we describe the design of the survey as well as the model
results. We used our WTP estimates to test the validity of thefor Pharmacoeconomics and Outcomes Research (ISPOR).
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ranging from cost-benefit analyses of air quality regulations to
evaluations of health programs.Previous Literature
Contingent valuation is a methodology for valuing changes in
health status. CV arose in the environmental economics litera-
ture as an approach to overcome the lack of markets for public
goods [6]. There have been more than 1500 applications of CV,
many dealing with environmental goods [7]. CV has increasingly
been applied to the valuation of health outcomes and regulatory
review of health policies [8,9]; however, previous authors have
noted that the overall quality of CV health studies is disappoint-
ing [8,10]. Policymakers have specifically noted the need for a
valuation of the burden of child asthma [10].
The validity of a CV study depends on the quality of the
hypothetical scenario, which should provide saliency through
realistic, detailed descriptions but should also avoid embedding
or anchoring to a reference good. The implementation of CV has
been thoroughly discussed in the environmental economics
context [11–13], but issues specific to health require further study,
especially given concerns in the health economics literature
regarding responses to hypothetical scenarios [8,14–16]. Most
health economics CV studies do not conform to existing guide-
lines for a robust CV study [8,14]. Smith [8] finds that the
hypothetical devices in 111 previous studies were poorly con-
structed and described. A valid CV study for environmental
[6,11–13] or health outcomes [17–19] requires a hypothetical
scenario that is realistic to the respondents and a sample that
is representative of the population of interest.
We explore these methodological issues through a study of
childhood asthma. There has been little research estimating WTP
to reduce asthma morbidity for children. Rowe and Chestnut [20]
used a broad scenario eliciting willingness to increase taxes to
‘‘set up programs that could reduce pollens, dusts, air pollutants,
and other factors.’’ Some studies on adult asthma [21–23] used CV
to elicit WTP for hypothetical medications that would eliminate
asthma symptoms or cure asthma. But these studies are in many
ways flawed: it is difficult to disentangle preferences for air
quality improvement from reductions in asthma morbidity [24];
survey responses include unmeasured bias against medications;
the sample of respondents may not accurately represent the
entire population of child asthma cases; and because improve-
ments in our understanding of asthma suggest that a complete
cure is not credible, the hypothetical presented is unrealistic.
Furthermore, these scenarios do not value the broader psycho-
social burden—uncertainty, daily management—associated with
asthma, and therefore do not address the real-life experiences of
respondent households. The stress caused by lacking control over
one’s health can have a detrimental effect on a broad range of
outcomes [25–27].Methods and Application
We examine four essential components of a credible health
valuation study.
Population of Interest
Studies show substantial disparities by race/ethnicity and income
in asthma-related hospitalizations, emergency room visits, and
school absences [28–30]. For these reasons, it is important to base
valuation estimates on a sample that reflects the increased pre-
valence of asthma morbidity among minority and low-income
households. The consensus approach is to sample individualswho are personally familiar with the health outcome [14,17–19]
and make household money allocation decisions. This is essential
for a chronic illness, because it is difficult for someone unaffected
by a disease to appreciate its full impact on the quality of personal
and family life. Our approach is consistent with that of previous
studies that value the impact of a health intervention on both the
child’s health and the overall quality of family life [31,32]. Last,
theoretical models suggest that parents are appropriate proxies for
children [10], and the difficulties of administering a CV survey to
children render doing so impractical.
Like Rowe and Chestnut [20] and Dickie and Gerking [33], we
administered two economic surveys (a revealed preference sur-
vey and a contingent valuation survey) to participants in an
asthma epidemiology study. This strategy reduces sample size
(because such studies typically have small enrollments) but
provides easy access to the target population. We combined our
economic study of household behaviors with epidemiological and
demographic data collected by the Fresno Asthmatic Children’s
Environment Study (FACES), a 5-year epidemiological study of
households with children aged 5 to 11 years with clinically
diagnosed asthma living in Fresno, CA.
Qualitative Study and Scenario Development
Families vary in their WTP for improvements in their children’s
asthma. They also vary in their beliefs about and attitudes toward
asthma [34–37], the degree to which the disease affects house-
hold quality of life [34,35,37], attitudes toward and trust in the
health care sector [37–39], and their perceptions of the risk of
asthma symptoms due to environmental pollution [40]. To the
extent that these attitudes and beliefs are related either to WTP
for medically irrelevant attributes of the valuation scenario or to
standard explanatory variables, ignoring these sources of hetero-
geneity will produce biased estimates. Therefore, we used a
preliminary qualitative study to measure these variables and
designed a scenario to minimize their influence.
First, we conducted a revealed preference survey of FACES
participants on four topics: health status, attitudes and beliefs,
averting behaviors and their perceived risks and benefits, and
socioeconomic characteristics. We supplemented the data from
this survey with data from the epidemiological study on the child’s
asthma morbidity. Next, we conducted three waves of focus groups
(four to five sessions with four to six participants each) to under-
stand health behaviors and influences on household choices from
the family’s perspective. Focus groups included families in the
Fresno area, Hampden and Hampshire counties in Massachusetts,
and Oakland, CA. FACES participants were included in the first two
waves but excluded from the third, so that we could administer the
CV survey to the complete FACES cohort.
In the first wave, discussion topics were drawn from three
models of health behaviors—the Health Belief Model, the Theory
of Reasoned Action, and the Theory of Social Cognition—and
covered perceptions regarding susceptibility to asthma, disease
severity, benefits from taking action, barriers preventing action,
health behaviors, and subjective norms concerning behavior. In
the second wave, we developed a specific hypothetical product
to be used in the CV scenario. The hypothetical product was
inspired by two products consistently mentioned by parents: the
pulmonary function tests used in the epidemiological study and
the fingertip oxygen monitor used in medical offices. In the third
wave, we identified the questions or concerns that respondents
might have about our product, and we tested different hypothe-
tical versions of it to minimize complicating issues.
This qualitative study provided three important lessons. First,
the nonmarket welfare effects of asthma include both acute
symptom episodes (physical effect) and the chronic stress caused
by the lack of control over the disease (psychosocial effect).
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child’s asthma status and discussed how uncertainty affected
their lives. Second, households in our population harbored nega-
tive views of medications and strong opinions about their possible
side effects. These attitudes toward medication are evident in
many other health studies. Third, the households sampled were
already engaged in a wide range of efforts to reduce asthma
episodes and generally felt that adding new activities or changing
routines was cumbersome and unattractive.
Hypothetical Scenario
In light of these considerations, we chose to present a product that
is used by the family rather than a change that is external to the
family (such as a shift in public policy). This avoided two sources of
unobserved heterogeneity: perception of the policy’s efficacy and
perception of the child’s responsiveness to the intended change
(e.g., reduction of pollution). To avoid confounding the WTP
response with preferences for different types of health care, we
decided not to include medication in our hypothetical. We chose a
scenario that did not require substantial behavioral changes
because participants may have varying perceptions of their ability
to change behavior. While the hypothetical device requires some
small behavioral changes, such as wearing the device (which is
similar to a wristwatch, described below) or adapting to a new
asthma ‘‘monitoring system,’’ households would not need to make
environmental changes or use new medical treatments. In the
focus groups, pilot survey, and final CV survey, families did not
express concern that substantial behavioral changes would be
required. Finally, we designed our scenario to target both physical
asthma symptoms and the stress caused by uncertainty.
The hypothetical product we offered was a ‘‘BreatheRight’’
oxygen monitor, worn like a wristwatch, which would provide
immediate, objective information about the child’s asthma status
(blood oxygen level). This product was similar to the fingertip
oxygen monitor that our population was familiar with and did
not require expending more time on asthma management (e.g.,
taking medication, reducing triggers). This asthma watch would
not only help families address medical symptoms but also
provide information to reduce uncertainty and stress. The sce-
nario included two optional, free services to deliver timely
information: ParentAlert, which notifies a guardian when the
monitor has changed to yellow or red, and ActionAlert, which
notifies the child’s physician.
In the final CV survey, individuals were presented with a
product brochure (a copy of the survey is available from the
authors on request). The brochure reviewed the two medical
components of asthma—inflammation and constriction—and
compared the watch to the actual oxygen monitor used in
emergency rooms in order to provide to participants a mean-
ingful reference. The brochure stated, ‘‘Children who wore the
watch had 50% fewer days with asthma symptoms’’ and ‘‘With
BreatheRight you know if asthma is affecting your child’s air-
ways. Monitoring with BreatheRight allows you to take prompt
action and decreases asthma symptoms.’’ The interviewer
reminded the respondent of the number of symptom-days she
had previously reported and the number of symptom-days the
watch would be expected to prevent. The respondent was then
asked whether she would be willing to pay certain specific
amounts for the watch; the price was presented as both monthly
payments and an annual total.
We used focus groups and the pilot survey to establish a
reasonable range of prices. Using an open-ended format, we
asked families to state how much they would be willing to pay for
the device. In the first round of pilot tests, we wrote on index
cards a range of prices from the minimum to the maximum given
in the focus groups. Respondents were asked to sort the pricesinto those they would not be willing to pay and those they would
be willing to pay. We used this approach to approximate the
randomly shuffled payment card method, which has been sug-
gested for contingent valuation in health [41]. These prices were
tested in the pilot survey to generate the prices offered in the
final CV survey.
Econometric Model
Our survey identified people who were interested in the watch
and those who were not. Only the former were presented with a
price; the interviewer then recorded their responses to a one-
and-one-half-bounded dichotomous choice [42]. In this approach,
a respondent is given two prices up-front and told that the exact
cost of the item lies within the range bounded by these two
prices. Of the two prices, one is selected randomly and the
respondent is asked whether she would be willing to pay it; she
is then asked whether she would be willing to pay the other price,
but only if this would be consistent with her initial response.
These responses provide a range for her WTP. All possible
responses can be summarized in three groups: (no, no), where
the respondent is unwilling to pay even the lower price; (yes, no),
where she is willing to pay the lower but not the higher price; and
(yes, yes), where she is willing to pay the higher price (econo-
metric details in [42]). The one-and-one-half-bounded [42] has
been shown to reduce some inconsistencies found in the double-
bounded format without compromising statistical efficiency.
We estimated the mean WTP for the sample by using both a
nonparametric and a parametric probability model with a linear
functional form for the utility function [43]; because results were
not qualitatively different, we report them only for the para-
metric estimation. Some respondents were not interested in the
device; we address this with three models. First, we excluded the
18 respondents who were not interested and estimated the
discrete choice models only for the others (model 1). Second,
we coded these 18 responses as saying ‘‘no’’ to any bid (model 2).
Third, we used these individuals to define a spike at zero (model
3). For each model, we compared three specifications: 1) a simple
model with the bid as the only explanatory variable, 2) a model
that adds health status and beliefs to the bid, and 3) a full model
that also includes sociodemographics.Results
Survey Data
Descriptive statistics for the population and sample are given in
Table 1. FACES completed a total of 315 baseline interviews (‘‘Full
FACES’’ column in the table). A total of 222 households completed
the baseline, provided complete epidemiological survey data, and
were also English-proficient. Of those households, 73 declined to
take the CV survey (‘‘Active FACES, decline CV’’ column), leaving
149 participants who completed the CV survey and provided
complete epidemiological data (‘‘CV’’ column). The CV survey was
administered in person by FACES employees in FACES offices to
the single family member primarily responsible for making
health care decisions for the child, without the child present.
The children covered in our data range in age from 7 to 17
years, with a mean age of 12.5 years. The larger proportion of
black/African-American participants in FACES relative to the
Fresno population likely reflects the difference in prevalence in
the California population [30]. The ‘‘CV’’ group contains a larger
proportion of whites, a smaller proportion of Hispanics, and
slightly more African Americans than the ‘‘Active FACES, decline
CV’’ group. We believe that this difference is a consequence of our
administering the survey only in English, whereas the FACES
Table 1 – Study sample.
Fresno
County
Full FACES
baseline
Active FACES,
decline CV
CV
(n ¼ 315) (n ¼ 73) (n ¼ 149)
Race/ethnicity
White 39.7 41.9 41.1 47.7
Hispanic 44.0 39.7 43.8 30.9
Black/African American 5.3 15.6 13.7 15.4
Other/missing NA 2.8 1.4 6.0
(n ¼ 315) (n ¼ 73) (n ¼ 149)
Own home 56.5 56.5 55.7 53.0
(n ¼ 294) (n ¼ 70) (n ¼ 125)
Maternal caregiver has high
school degree or higher
69.0 84.9 88.7 89.9
(n ¼ 311) (n ¼ 71) (n ¼ 145)
Income
Less than 30,000 43.2 45.4 50.7 30.6
31,000–50,000 23.1 25.0 17.8 25.9
More than 50,000 33.7 29.6 31.5 43.5
(n ¼ 304) (n ¼ 73) (n ¼ 147)
Statistics for the full FACES baseline are from Tager et al., Fresno Asthmatic Children’s Environment Study (FACES) Final Report (ARB Contract
Nos. 99-322). Sacramento, CA: Research Division California Air Resources Board, 2006. Note. Because of missing observations for some
variables, the sample statistics have slightly smaller sample sizes than the number of observations (304 of the 315 ‘‘Full FACES’’ group and 147
of the ‘‘CV’’ had no missing data). CV, contingent valuation; FACES, Fresno Asthmatic Children’s Environment Study; NA, not applicable.
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 7 7 – 1 0 8 31080surveys were administered in English or Spanish. Our sample is
more representative of families affected by asthma than the
samples used in the previously cited studies.
Estimation Results
The set of prices offered for the watch was (5, 15, 20, 30, 55, 60, 65,
80, 90, 100, 125). A total of 153 CV surveys were completed (149Table 2 – Descriptive statistics and definitions of explanatory v
Name De
Health Status
Overall health Overall health of child: 1 for excel
Bad days Number of bad days with asthma
Length Length of time since last bad day:
Severity of asthma Severity of asthma in general: 1 fo
Severity of attacks Severity of an attack: 1 for the low
Symptom frequency Number of days with symptoms i
Attitudes and Beliefs
Prevent attack Do they think they can prevent an
Control attack Do they think they can control an
Worry Do they worry about asthma betw
Typical Are current symptoms typical for
Asthma rank Do they rank asthma as the prima
Asthma parents Has a parent been diagnosed with
Triggers Do parents report that physical ac
Demographics
Income Is incomeo $40,000/y? 1 for yes.
No Rx Has child foregone a RX because o
Financial stress Do they rank family finances as p
Race Does parent report white/Caucasi
Mother’s education Does mother have less than high
Gender Is child male? 1 for yes.
Parents’ overall health Is parent in excellent health? 1 fo
Rx, treatment.with complete data on covariates of interest). Of the 153, 18
respondents (11.76%) did not want the watch, 56 (36.60%) were
willing to pay the higher price, 50 (32.68%) were willing to pay the
lower but not the higher price, and 29 (18.95%) were unwilling to
pay either price.
Descriptive statistics for our explanatory variables are given in
Table 2. Results of the parametric models are presented in Table 3.
In all models, the bid variable is of the expected sign andariables.
finition Mean7 s.d.
lent or very good. 0.570 7 0.497
: 1 for fewer than two a month. 0.564 7 0.498
1 for less than 3 months. 0.503 7 0.502
r the lowest level. 0.362 7 0.482
est level. 0.081 7 0.273
n past 30 days. 8.430 7 7.265
attack? 1 for yes. 0.617 7 0.488
attack once started? 1 for yes. 0.383 7 0.488
een episodes? 1 for often or sometimes. 0.671 7 0.471
child? 1 for yes. 0.624 7 0.486
ry stressor? 1 for yes. 0.322 7 0.469
asthma? 1 for yes. 0.443 7 0.498
tivity is a trigger for asthma? 1 for yes. 0.403 7 0.492
0.611 7 0.489
f price? 1 for yes. 0.255 7 0.437
rimary stressor? 1 for yes. 0.235 7 0.425
an as child’s race/ethnicity? 1 for yes. 0.477 7 0.501
school education? 1 for yes. 0.074 7 0.262
0.642 7 0.482
r yes. 0.174 7 0.381
Table 3 – Parametric models.
Category Variable Model (1) Model (2) Model (3)
Excluding WTP ¼ 0 WTP ¼ 0 are no-no Spike model
A B C A B C A B C
Cost variable Constant 2.925* 2.030* 2.402* 2.370* 1.619* 2.313* 1.827* 0.998* 1.846*
t value (9.263) (3.968) (2.734) (9.884) (3.62) (2.766) (8.395) (2.298) (2.325)
BID Bid  0.0453*  0.049*  0.0493*  0.0419*  0.0492*  0.0495*  0.033*  0.0379*  0.0382*
t value (  9.781) (  9.768) (  9.755) (  11.297) (10.978) (  10.986) (  10.101) (  9.936) (  9.94)
Health status Overall health —  0.224  0.125 —  0.603†  0.532* —  0.619†  0.537
t value — (  0.588) (  0.318) — (  1.682) (  1.453) — (  1.773) (  1.496)
Symptoms — 0.054 0.055 — 0.078† 0.0817† — 0.075† 0.081†
t value — (1.11) (1.118) — (1.665) (1.735) — (1.658) (1.772)
Attitudes and beliefs Control attack — 0.525 0.503 — 0.764* 0.794* — 0.800* 0.839*
t value — (1.405) (1.324) — (2.197) (2.272) — (2.360) (2.453)
Worry — 0.767† 0.828* — 0.938* 0.963* — 0.897* 0.935*
t value — (1.909) (2.023) — (2.578) (2.618) — (2.522) (2.592)
Asthma rank — 0.762† 0.765† — 0.807* 0.820* — 0.740† 0.739†
t value — (1.855) (1.801) — (2.016) (1.978) — (1.941) (1.875)
Sociodemographics Age — —  0.028 — —  0.061 — —  0.078
t value — — (  0.414) — — (  0.992) — — (  1.308)
Race — —  0.160 — —  0.037 — —  0.026
t value — — (  0.421) — — (  0.11) — — (  0.079)
Mother’s education — —  0.793 — —  0.665 — —  0.520
t value — — (  1.121) — — (  1.028) — — (  0.817)
E Estimated spike — — — — — — 0.139 0.108 0.108
N 131 131 131 149 149 149 149 149 149
Log-likelihood  144.23  136.37  135.63  192.50  176.39  175.41  187.42  171.53  170.35
Mean monthly WTP 64.62 64.84 64.79 56.48 56.60 56.52 60.67 59.76 59.69
SD 3.84 3.68 3.68 3.80 3.37 3.37 4.45 4.06 4.07
Average WTP per
day of symptoms
17.05 17.11 17.10 14.90 14.93 14.91 16.01 15.77 15.75
WTP assuming asthma rank ¼ 0 and worry ¼ 0
Mean monthly WTP 48.27 38.52 40.67
Mean WTP per day of symptoms 12.70 10.33 10.90
Note. Columns ‘‘A’’ include only the price of the hypothetical good as an independent variable. Columns ‘‘B’’ include price and asthma beliefs. Columns ‘‘C’’ include the price, beliefs, and
sociodemographics.
WTP, willingness to pay.
* Po 0.05
† Po 0.1
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VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 7 7 – 1 0 8 31082statistically significant. The mean WTP for the reductions in
asthma morbidity calculated from the parametric models ranges
from $56.487 $3.80 to $64.847 $3.68 per month. To address yea-
saying, we recalculated the WTP by using a 10-point certainty
calibration scale [44]. ‘‘Yes’’ responses that were followed by a
certainty level of less than 8 were recoded as ‘‘no’’ responses. The
mean WTP values for our models remained similar, ranging from
$48.58 to $56.72. The difference between the original and recali-
brated WTP ranged from $5.91 (in the spike model with all
covariates) to $8.27 (model 1 with only price): there was significant
overlap in the 95% confidence interval for many of the models.
Scenario Validity
Our survey extensively asked respondents to describe their percep-
tions of the product and the reasons for their choice. The over-
whelming majority reported only asthma-related benefits as the
basis for the decision, with reduced stress from improved informa-
tion a prevailing theme. Of the 135 households willing to buy the
watch, the vast majority cited as motivation decreased uncertainty,
peace of mind, reduced worry, or similar benefits. Participants
valued improved information because it would reduce anxiety
about the child’s health. Of those stating that they would buy the
watch, 87% opted for ParentAlert (alone or with ActionAlert). People
reported that this service would help them monitor the child’s
health, provide peace of mind, reduce worries, and reduce stress.
The only reported nonasthma benefit was that the watch would
also tell time. Only three respondents reported concerns about
accuracy; only four reported that they were uncertain whether, for
fashion reasons, their child would be willing to wear the watch. It is
plausible that the age of the child might affect the parent’s
perception of the efficacy of the monitor; however, the age of the
child was not statistically significant in our model.
Of the 18 respondents who were not interested in the product,
only two expressed concerns about its effectiveness. The others
were ‘‘not interested’’ because their child’s asthma was mild or
under control. The primary reasons given for not buying the
watch at the offered price were that the child’s asthma was not
significant enough to warrant the purchase and that the house-
hold budget was limited. Of those who declined the watch, 63%
would have bought it at another time when the child’s asthma
was worse than at the time of the survey. These responses
indicate that the WTP elicited by the scenario was predominantly
based on asthma-related impacts and that the scenario had a
high degree of acceptance.
Our estimated WTP was also consistent with observed house-
hold behaviors. Expenditures on asthma-related goods, including
supplies for reducing triggers, medications, and the amortized cost
of durable goods, are highly right-skewed with a median of $492.75 a
year or about $41 a month (mean ¼ $644.677 $499.92, range
$0–$2490.85). The median proportion of household income spent
on these goods was 1.1% (mean ¼ 2.6%7 4.2%). The median
income share for our WTP estimates is 1.5% (mean ¼ 2.4%7 1.9%).
This convergent validity increases our confidence in the estimates.Discussion
Our results reveal how asthma affects household decisions. WTP
decreases if the child has a higher level of overall health. WTP
increases if asthma is ranked as a primary stressor, the respon-
dent feels able to control an asthma attack once it starts, or the
respondent worries about the child’s asthma between episodes.
Symptom frequency is positively associated with WTP, but its
coefficient is substantially smaller than those for ‘‘control
attack,’’ ‘‘worry,’’ and ‘‘asthma rank.’’ Of particular interest is the
contrast between the variables that were significant and thosethat were not. Remarkably, measures of symptom frequency
were not significant. In the health economics literature, health
status is typically measured by using objective disease character-
istics such as symptom frequency or some measure of health
care utilization. These variables, however, do not accurately
reflect how a family experiences the disease. Our results show
that WTP depends less on objective severity measures and more
on attitudes and beliefs, such as the degree of worry between
attacks and the importance of asthma as a family stressor.
As with any CV study, these results require several qualifica-
tions. First, some parents might have felt obliged to inflate their
WTP because they were asked in person about a product that
could improve their child’s health. The NOAA guidelines [11] and
summaries of best practices [11,45,46], however, suggest that
in-person interviews are preferable to other approaches. We
reestimated WTP by using a numerical certainty scale [44] and
retaining positive responses only from those participants who
were highly certain of their answers; this yielded similar results.
Second, CV studies are subject to the incompatible incentive
dilemma. A respondent might misreport her true WTP if she
believes that her response affects the provision of policy or
programs [6]. The consensus in the CV literature is that this
problem is avoided by using a binary discrete choice format with
a take-or-leave-it question that is resistant to such biases [6,47],
as we did in our survey. Third, sample selection is a common
issue in observational studies. The sociodemographic character-
istics of our sample, however, do not vary systematically from the
population of interest: households in Fresno with children with
asthma. Fourth, our sample size was limited, as is common in
epidemiological studies [48,49]. Other possible strategies might
yield a greater sample size but would make it harder to follow up
with respondents or to link the CV survey with epidemiological
data. Given that the sample reasonably approximates the popu-
lation of interest, we felt the advantage of detailed data out-
weighed the benefits of a larger sample.Conclusions
Public health policy requires accurate cost-benefit analyses,
which require accurate valuations of the health outcomes tar-
geted by policy. However, valuations of the disutility caused by
chronic illnesses typically suffer from a variety of shortcomings,
including unrealistic scenarios, confounding of preferences for
health outcomes with preferences for other scenario attributes,
and failure to capture the psychosocial effects of illness in
addition to its physical effects.
Our contingent valuation study estimates parental WTP for
reduced asthma severity in children. We calculate a mean WTP of
$56.48 to $64.84 per month for the benefits provided by our
scenario. This estimate can be used to quantify the benefits of
policy initiatives related to asthma. Our estimate goes beyond
previous studies because it incorporates both the disutility of
physical symptoms and the disutility caused by uncertainty and
stress.
In addition, our study provides detailed new guidance on how
to construct a CV scenario for a chronic illness. We used house-
hold perceptions of health states and of the factors that affect
health states to inform our CV scenario, to make it credible to
survey participants, and to ensure that participant choices were
not unduly affected by unintended attributes of the scenario.
Household perceptions and beliefs, such as perceptions of the
overall burden that asthma places on a family, had a larger impact
on valuation than traditional measures of asthma severity.
Our approach can be applied to other chronic illnesses, such
as diabetes or chronic pain, with which asthma shares several
important characteristics: frequency and severity fluctuate over
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 7 7 – 1 0 8 3 1083time; health outcomes depend on both exogenous factors and
individual behaviors; in general, the impact on quality of life is
determined less by physiological severity than by the family’s
experience of the disease; and both disease prevalence and the
value placed on disease mitigation vary across subpopulations.
These characteristics make it difficult to value reductions in
morbidity from chronic illnesses; it is important to develop ‘‘best
practice’’ guidelines similar to those in environmental economics
[11,45,46]. This article shows how detailed fieldwork and empiri-
cal modeling can be combined to overcome these challenges and
derive reliable valuations of the impact of chronic illnesses.Acknowledgments
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